The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1498-1507

  Koutcher, Jason A ^a   Motwani, Monica ^a   Zakian, Kristen L ^a   Li, Xiao Kui ^a   Matei, Cornelia ^a   Dyke, Jonathan P ^a   Ballon, Douglas ^a   Yoo, Hyok He ^a   Schwartz, Gary K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN 1; PACLITAXEL;

ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; TUMOR BLOOD FLOW; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CDC2 PROTEIN KINASE; CELL DIVISION; ENERGY METABOLISM; HUMANS; HYDROGEN-ION CONCENTRATION; LACTONES; MACROLIDES; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED C3H; MITOSIS; NEOPLASMS, EXPERIMENTAL; PACLITAXEL; PHOSPHOCREATINE; REGIONAL BLOOD FLOW; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0034006706     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Hornung, R. L., Pearson, J. W., Bechwith, M., and Longo, D. L. Preclinical evaluation of bryostatin-1 as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res., 52: 101-107, 1992.
2. Schucter, L. M., Esa, A. H., and May, W. S. Successful treatment of murine melanoma with bryostatin-1. Cancer Res., 51: 682-687, 1991.
3. Stanwell, C., Geischer, A., Bradshaw, T. D., and Petit, G. R. The role of protein kinase C isoenzymes in human inhibition caused by bryostatin-1 in human A549 lung and MCF-7 breast carcinoma cells. Int. J. Cancer, 56: 585-592, 1994.
4. Hennings, H., Blumberg, P. M., Petit, P. M., Herald, C. L., Shores, R., and Yuspa, S. Bryostatin-1, activator of protein kinase C inhibits, tumor promotion by phorbol esters in sencar mouse skin. Carcinogenesis (Lond.), 9: 1343-1346, 1987.
5. Asiedu, C., Biggs, J., Lilly, M., and Kraft, A. S. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin dependent kinase 2. Cancer Res., 55: 3716-3720, 1995.
6. Szallasi, Z., Linh, D., Levine, R., Lewin, N. E., Nguyen, P. N., Williams, M. D., Pettit, G. R., and Blumberg, P. M. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Cancer Res., 56: 2105-2111, 1996.
7. Philip, P. A., Rea, D., Thavasu, P., Carmichael, J., Nicholas, S. A., Rockett, H., Talbot, D. C., Ganesman, T., Petit, G. R., Balkwill, F., and Harris, A. L. Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor a induction in vivo. J. Natl. Cancer Inst., 85: 1812-1818, 1993.
8. Mohr, H., Pettit, G. R., and Plessing-Menze, A. Co-induction of lymphokine synthesis by the antineoplastic bryostatins. Immunobiology, 175: 420-430, 1987.
9. Hickman, P. F., Kemp, G. J., Thompson, C. H., Salisbury, A. J., Wade, K., Harris, A. L., and Radda, G. K. Bryostatin-1, a novel antineoplastic agent and protein kinase C activator induces human myalgia and muscle metabolic defects: a 31P magnetic resonance spectroscopic study. Br. J. Cancer, 72: 998-1003, 1995.
10. Thompson, C. H., Macauleay, V. M., O'Byrne, K. J., Kemp, G. J., Wilner, S. M., Talbot, D. C., Harris, A. L., and Radda, G. K. Modulation of bryostatin-1 toxicity by nifedipine: effects on muscle metabolism and oxygen supply. Br. J. Cancer, 73: 1161-1164, 1996.
11. Jayson, G. C., Crowther, D., Prendiville, J., McGowan, A. T., Scheid, C., Stern, P., Young, R., Brenchley, P., Chang, J., Owens, S., and Pettit, G. R. A Phase I trial of bryostatin-1 in patients with advanced malignancy using a 24-hour intravenous infusion. Br. J. Cancer, 72: 461-468, 1995.
12. Prendiville, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGowan, A., Testa, N., Stern, P., McDermott, R., Potter, M., and Pettit, G. R. A Phase I study of intravenous bryostatin-1 in patients with advanced cancer. Br. J. Cancer, 68: 418-424, 1993.
13. Grant, S., Roberts, J., Poplin, E., Tombes, M. B., Kyle, B., Welch, D., Carr, M., and Bear, H. D. Phase Ib trial of bryostatin-1 in patients with refractory malignancies. Clin. Cancer Res., 4: 611-618, 1998.
14. Jarvis, W. D., Povirk, L. F., Turner, A. J., Traylor, R. S., Gewirtz, D. A., Pettit, G. R., and Grant, S. Effects of bryostatin-1 and other pharmacological activators of protein kinase C on 1-β-D-arabinofurano-sylcytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem. Pharmacol., 47: 839-852, 1994.
15. Mohammad, R. M., Diwakaran, H., Maki, A., Emarra, M. A., Pettit, G. R., Redman, B., and al-Katib, A. Bryostatin-1 induces apoptosis and augments inhibitory effects of vincristine in human diffuse large cell lymphoma. Leuk. Res., 19: 667-673, 1995.
16. Mohammad, R. M., al-Katib, A., Pettit, G. R., and Sensenbrenner, L. L. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res., 54: 165-168, 1994.
17. Basu, A, and Lazo, J. S. Sensitization of human cervical carcinoma cells to cis-diamminedichloroplatinum (II) by bryostatin-1. Cancer Res., 52: 3119-3124, 1992.
18. Wang, S., Guo, C. Y., Castillo, A., Dent, P., and Grant, S. Effect of bryostatin-1 on Taxol-induced apoptosis and cytotoxicity in human leukemia cells (U937). Biochem. Pharmacol., 56: 635-644, 1998.
19. Motwani, M., Delohery, T. M., and Schwartz, G. K. Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res., 5: 1876-1883, 1999.
20. Koutcher, J. A., Alfieri, A. A., Devitt, M. L., Rhee, J. G., Kornblith, A. B., Mahmood, U., Merchant, T. E., and Cowburn, D. Quantitative changes in tumor metabolism, partial pressure of oxygen, and radiobiological oxygenation status postradiation. Cancer Res., 52: 4620-4627, 1992.
21. Reddick, W., Langston, J., Meyer, W., Gronemeyer, S., Steen, R., Chen, G., and Taylor, J. Discrete signal processing of dynamic contrast-enhanced MR imaging: statistical validation and preliminary clinical application. J. Magn. Reson. Imaging, 4: 397-404, 1994.
22. Erlemann, R., Sciuk, J., Bosse, A., Ritter, J., Kusnierz-Glaz, C., Peters, P., and Wuisman, P. Response of osteosarcoma and Ewing sarcoma to preoperative chemotherapy: assessment with dynamic and static MR imaging and skeletal scintigraphy. Radiology, 175: 791-796, 1990.
23. Seidman, A. D., Hudis, C. A., Raptis, G., Baselga, J., Fennelly, D., and Norton, L. Paclitaxel for breast cancer: the Memorial Sloan-Kettering Cancer Center experience. Oncology (Huntingt.), 11 (Suppl. 2): 20-28, 1997.
24. Poon, R. Y. C., Chau, M. S., Yamashita, K., and Hunter, T. The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res., 57: 5168-5178, 1997.
25. Nurse, P. Universal control mechanism regulating onset of M-phase. Nature (Lond.), 344: 503-508, 1990.
26. Vandre, D. D., and Borisy, G. G. Anaphase onset and dephosphorylation of mitotic phosphoproteins occur concomitantly. J. Cell Sci., 94: 245-258, 1989.
27. Martin, D. S., and Schwartz, G. K. Chemotherapeutically induced DNA damage, ATP depletion, and the apoptotic biochemical cascade. Oncol. Res., 9: 1-5, 1997.
28. Belfi, C. A., Ting, L. L., Hassenbusch, S. J., Tefft, M., and Ngo, F. Q. H. Determination of changes in tumor blood perfusion after hydralazine treatment by dynamic paramagnetic-enhanced magnetic resonance imaging. Int. J. Radiat. Oncol. Biol. Phys., 22: 477-482, 1992.
29. Kennedy, S. D., Szczepaniak, L. S., Gibson, S. L., Hilf, R., Foster, T. H., and Bryant, R. G. Quantitative MRI of Gd-DTPA uptake in tumors: response to photodynamic therapy. Magn. Reson. Med., 31: 292-301, 1994.
30. Schiff, P. B., and Horwitz, S. B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77: 1561-1565, 1980.
31. Jordan, M. A., Wendell, K., Gardiner, S., Derr, W. B., Copp, H., and Wilson, L. Mitotic block induced in Hela cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res., 56: 816-825, 1996.
32. cdc2 kinase activation and apoptosis inhibited by 12-O-tetradecanoylphorbol-13-acetate in human breast MCF-7 carcinoma cells. Cell Growth Differ., 9: 23-29, 1998.
33. 8triphosphate hydrolysis. Biochemistry, 22: 4814-4822, 1983.
34. Vulevic, B., and Correia, J. J. Thermodynamic and structural analysis of microtubule assembly: role of GTP hydrolysis. Biophys. J., 72: 1357-1375, 1997.
35. Reynolds, J. E., Li, J., Craig, R. W., and Eastman, A. BCL-2 and MCL-1 expression in Chinese hamster ovary cells inhibits intracellular acidification and apoptosis induced by staurosporine. Exp. Cell Res., 225: 430-436, 1996.
36. Chen, Q., Benson, R. S. P., Whetton, A. D., Brant, S. R., Donowitz, M., Montrose, M. H., Dive, C., and Watson, A. J. M. Role of acid/base homeostasis in the suppression of apoptosis in haemopoietic cells by v-Ab1 protein tyrosine kinase. J. Cell Sci., 110: 379-387, 1997.
37. Gottlieb, R. A., Nordberg, J., Skowronski, E., and Babior, B. M. Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification. Proc. Natl. Acad. Sci. USA, 93: 654-658, 1996.
38. Vukovic, V., and Tannock, I. F. Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone, and topotecan. Br. J. Cancer, 75: 1167-1172, 1997.
39. Kaubisch, A., Kelsen, D. R., Saltz, L., Kemeny, N., O'Reilly, E., Ilson, D., Endres, S., Barazzuol, J., and Schwartz, G. K. A Phase I trial of weekly sequential bryostatin-1 and paclitaxel in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol., 18: 166a, 1999.